Dexcom INC Form 4 insider transactions

Dexcom's Executive Vice President and Chief Legal Officer, Michael Jon Brown, sold 500 shares of common stock for $86.03 per share on July 15, 2025, under a pre-arranged 10b5-1 plan.

Dexcom Director Renee D. Gala filed an amended Form 4 to correct a previously misreported grant of 1,161 unvested restricted stock units.

Dexcom's EVP, Chief HR Officer, Sadie Stern, sold 1,466 shares of common stock for $85.06 per share on June 26, 2025, as part of a pre-arranged 10b5-1 trading plan.

DexCom Inc. Director Mark G. Foletta reported the sale of 2,750 shares of common stock at a weighted average price of $83.129 per share, executed under a pre-arranged 10b5-1 trading plan.

Dexcom's EVP and Chief Legal Officer, Michael Jon Brown, sold 500 shares of common stock for $82.8 per share on June 16, 2025, as part of a pre-established 10b5-1 trading plan.

DexCom Inc. Director Nicholas Augustinos reported the sale of 6,290 shares of common stock in two transactions in mid-June 2025, executed under a pre-arranged 10b5-1 trading plan.

Sadie Stern, Executive Vice President and Chief HR Officer of Dexcom Inc. (DXCM), reported the sale of 6,184 shares of common stock for approximately $526,300, executed under a Rule 10b5-1 trading plan.

Dexcom's EVP and Chief Legal Officer, Michael Jon Brown, sold 10,000 shares of common stock for approximately $84.28 per share, as part of a pre-established 10b5-1 trading plan.

Dexcom Inc.'s Executive Vice President and Chief Commercial Officer, Jon Coleman, has been granted 68,738 shares of common stock in the form of restricted stock units, aligning executive interests with shareholder value.

Director Rimma Driscoll reports acquisition of Dexcom stock via restricted stock units (RSUs) and disposal of shares.

Director Renee D. Gala reports acquisition of 5,074 shares of DexCom stock and disposal of shares to cover taxes.

Director Kyle Malady reports acquisition of 5,192 shares of Dexcom stock via restricted stock units (RSUs) and disposal of 23,334 shares.

Karen M. Dahut, a director at Dexcom Inc., transferred shares of common stock from direct ownership to a trust, according to a recent SEC filing.

Director Bridgette P. Heller reports acquiring 5,046 shares of DexCom Inc. common stock through a restricted stock unit (RSU) award.

Nicholas Augustinos, a director at DexCom Inc., reported a transfer of shares to a revocable trust and the grant of restricted stock units.

Mark G. Foletta, a director at Dexcom Inc., transferred shares to a family trust and received restricted stock units (RSUs) according to a recent SEC filing.

Director Richard Alexander Collins transferred shares to a revocable trust and received a restricted stock unit (RSU) award from Dexcom Inc.

Steven Altman, a director at DexCom Inc., reported a transfer of shares to a family trust and the grant of restricted stock units.

Eric Topol, a director at Dexcom Inc., transferred shares from direct ownership to Topol Family Holdings, LLC following the vesting of restricted stock units.

Director Bridgette P. Heller sold 352 shares of DexCom Inc. common stock at $70.33 per share on March 17, 2025, under a pre-arranged 10b5-1 trading plan.

Executive Vice President and Chief Operating Officer of Dexcom, Jacob Steven Leach, reports selling shares to cover tax withholding obligations related to vesting restricted stock units.

EVP and Chief Legal Officer of Dexcom, Michael Jon Brown, sold 13,000 shares of common stock to cover tax withholding obligations related to vesting RSUs.

Executive Vice President and Chief Financial Officer of Dexcom Inc., Jereme M. Sylvain, sold 12,001 shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

Sadie Stern, EVP and Chief HR Officer of Dexcom Inc., sold 11,176 shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

Dexcom's CEO, Kevin Sayer, sold 32,498 shares of common stock on March 12, 2025, to cover tax withholding obligations related to the vesting of restricted stock units.

Dexcom's CEO, Kevin Sayer, reports the acquisition of 85,490 shares of common stock through a grant of restricted stock units.

DexCom's EVP, Chief Operating Officer Jacob Steven Leach, reports acquisition of shares through restricted stock units and holdings in a family trust.

Sadie Stern, EVP and Chief HR Officer of DexCom, reports the acquisition of restricted stock units and resulting beneficial ownership of DexCom stock.

EVP and Chief Legal Officer of DexCom, Michael Jon Brown, reports the acquisition of restricted stock units.

EVP and CFO of Dexcom, Jereme Sylvain, reports the acquisition and disposal of Dexcom common stock, including grants of restricted stock units (RSUs) and sales of shares on March 8th and 10th, 2025.